Oryzon Genomics S.A. (0RDB.L)
EUR 2.74
(-1.44%)
EUR 2.74
(-1.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.42 Million USD | -7.8% |
| 2022 | 22.14 Million USD | 17.23% |
| 2021 | 18.89 Million USD | 16.24% |
| 2020 | 16.25 Million USD | 6.01% |
| 2019 | 15.33 Million USD | 42.37% |
| 2018 | 10.76 Million USD | 5.25% |
| 2017 | 10.23 Million USD | 5.61% |
| 2016 | 9.68 Million USD | 24.78% |
| 2015 | 7.76 Million USD | -18.03% |
| 2014 | 9.47 Million USD | 64.99% |
| 2013 | 5.74 Million USD | 241.08% |
| 2012 | -4.06 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.29 Million USD | 199.79% |
| 2024 Q1 | 1.09 Million USD | -23.41% |
| 2023 Q2 | 9.07 Million USD | 557.43% |
| 2023 FY | 5.02 Million USD | -77.3% |
| 2023 Q1 | 1.38 Million USD | -92.43% |
| 2023 Q4 | 1.43 Million USD | 73.73% |
| 2023 Q3 | 826 Thousand USD | -90.9% |
| 2022 Q2 | 8.85 Million USD | 407.52% |
| 2022 Q1 | 1.74 Million USD | -86.83% |
| 2022 FY | 22.14 Million USD | 17.23% |
| 2022 Q4 | 18.24 Million USD | 2563.02% |
| 2022 Q3 | 685 Thousand USD | -92.27% |
| 2021 Q3 | 1.8 Million USD | -75.0% |
| 2021 Q2 | 7.2 Million USD | 252.32% |
| 2021 FY | 18.89 Million USD | 16.24% |
| 2021 Q4 | 13.24 Million USD | 635.88% |
| 2021 Q1 | 2.04 Million USD | -47.05% |
| 2020 Q1 | -4.52 Million USD | -214.53% |
| 2020 FY | 16.25 Million USD | 6.01% |
| 2020 Q4 | 3.86 Million USD | 256.74% |
| 2020 Q3 | -2.46 Million USD | 22.08% |
| 2020 Q2 | -3.16 Million USD | 30.08% |
| 2019 FY | 15.33 Million USD | 42.37% |
| 2019 Q4 | 3.94 Million USD | 205.7% |
| 2019 Q2 | 4.06 Million USD | 243.18% |
| 2019 Q1 | -2.83 Million USD | -205.37% |
| 2019 Q3 | -3.73 Million USD | -191.84% |
| 2018 Q3 | -2.28 Million USD | -181.62% |
| 2018 Q4 | 2.69 Million USD | 217.94% |
| 2018 FY | 10.76 Million USD | 5.25% |
| 2018 Q2 | 2.79 Million USD | 218.4% |
| 2018 Q1 | -2.36 Million USD | -209.59% |
| 2017 Q2 | 2.89 Million USD | 237.8% |
| 2017 Q1 | -2.09 Million USD | -185.64% |
| 2017 Q4 | 2.15 Million USD | 202.79% |
| 2017 Q3 | -2.09 Million USD | -172.59% |
| 2017 FY | 10.23 Million USD | 5.61% |
| 2016 Q3 | -2.43 Million USD | -187.9% |
| 2016 FY | 9.68 Million USD | 24.78% |
| 2016 Q4 | 2.45 Million USD | 200.73% |
| 2016 Q2 | 2.76 Million USD | 242.64% |
| 2016 Q1 | -1.94 Million USD | -205.21% |
| 2015 Q4 | 1.84 Million USD | 212.74% |
| 2015 Q1 | -1.7 Million USD | -251.65% |
| 2015 Q2 | 2.34 Million USD | 237.56% |
| 2015 FY | 7.76 Million USD | -18.03% |
| 2015 Q3 | -1.63 Million USD | -169.65% |
| 2014 Q4 | 1.12 Million USD | -4.09% |
| 2014 Q2 | -2.98 Million USD | 0.0% |
| 2014 Q3 | 1.17 Million USD | 139.35% |
| 2014 FY | 9.47 Million USD | 64.99% |
| 2014 Q1 | -2.98 Million USD | 0.0% |
| 2013 FY | 5.74 Million USD | 241.08% |
| 2012 FY | -4.06 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Boiron SA | 317.27 Million EUR | 93.564% |
| Laboratorios Farmaceuticos Rovi, S.A. | 263.09 Million EUR | 92.238% |
| Vetoquinol SA | 217.11 Million EUR | 90.595% |
| Valneva SE | 134.92 Million EUR | 84.865% |
| AB Science S.A. | 14.01 Million EUR | -45.696% |
| Nanobiotix S.A. | 62.98 Million EUR | 67.579% |
| PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 18.271% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 17.298% |
| BioSenic S.A. | 7.58 Million EUR | -169.296% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 83.968% |
| Formycon AG | 23.73 Million EUR | 13.956% |